Cost of ranibizumab port delivery system for treating nAMD examined

For patients with neovascular age-related macular degeneration (nAMD), ranibizumab with a port delivery system (PDS) with one refill costs more than intravitreal ranibizumab or aflibercept injections if about 11 or 10 injections, respectively, or fewer are needed within the first year, according to a study published online June 16 in JAMA Ophthalmology.

This post was originally published on this site

Skip The Dishes Referral Code

KeyLegal.ca - Consult a Lawyer Online in a variety of legal subjects